CXCR4 and neoplasm: Further research and clinical trials are warranted to understand better the complex role of CXCR4 (particularly the expression of the ligand-activated p S339 form of CXCR4) in cancer progression and to explore potential strategies for the effective therapeutic targeting of this axis in different tumor types, including GBC.